Search Results
Jun 16, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit
More news about: Lakewood-Amedex Biotherapeutics Inc.
Jun 16, 2026, 08:00 ET Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). The Company's preclinical
More news about: Acurx Pharmaceuticals, Inc.
May 27, 2026, 09:00 ET Affinius Capital-Led Investor Consortium Completes $3.5 Billion Acquisition of Veris Residential
JERSEY CITY, N.J., May 27, 2026 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE, "Veris" or the "Company"), a Northeast-focused, Class A multifamily real estate investment trust (REIT), today announced that an investor consortium
More news about: Veris Residential, Inc.
May 27, 2026, 08:02 ET Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 21, 2026, 18:03 ET Universal Technical Institute and Peloton Interactive Set to Join S&P SmallCap 600
of trading on Wednesday, May 27. Universal Technical Institute Inc. (NYSE: UTI) will replace Veris Residential Inc. (NYSE: VRE). Affinius Capital and Vista Hill Partners are acquiring Veris Residential in a deal expected to be completed soon, pending final closing conditions.Peloton
More news about: S&P Dow Jones Indices
May 18, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
antibiotic-resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and others.About Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT)
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 14, 2026, 17:25 ET Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-xoma-ogn-vre-obtaining-fair-deals-for-their-shareholders-302772798.htmlSOURCE
More news about: Halper Sadeh LLP
May 12, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit
More news about: Lakewood-Amedex Biotherapeutics Inc.
May 12, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).Acurx's lead product
More news about: Acurx Pharmaceuticals, Inc.
May 04, 2026, 08:00 ET Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product
More news about: Acurx Pharmaceuticals, Inc.
May 01, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
antibiotic-resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and others.In laboratory studies using a serial passage of E. coli and MRSA in the presence of Nu-3 for 21 days, Nu-3 showed slightly
More news about: Lakewood-Amedex Biotherapeutics Inc.
Apr 29, 2026, 08:00 ET Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).Acurx's lead product
More news about: Acurx Pharmaceuticals, Inc.
Apr 28, 2026, 07:33 ET Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit
More news about: Lakewood-Amedex Biotherapeutics Inc.
Apr 23, 2026, 10:42 ET Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit
More news about: Lakewood-Amedex Biotherapeutics Inc.
Apr 20, 2026, 18:59 ET Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-cco-ehab-apls-vre-obtaining-fair-deals-for-their-shareholders-302747811.htmlSOURCE
More news about: Halper Sadeh LLP
Apr 20, 2026, 08:00 ET Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate,
More news about: Acurx Pharmaceuticals, Inc.
Apr 16, 2026, 16:01 ET Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).Acurx's lead product
More news about: Acurx Pharmaceuticals, Inc.
Apr 16, 2026, 08:00 ET Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).Acurx's lead product
More news about: Acurx Pharmaceuticals, Inc.
Apr 14, 2026, 12:55 ET Are VRE, SEM, TWO Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-vre-sem-two-obtaining-fair-deals-for-their-shareholders-302741932.htmlSOURCE
More news about: Halper Sadeh LLP
Mar 30, 2026, 07:01 ET Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate,
More news about: Acurx Pharmaceuticals, Inc.
Mar 27, 2026, 05:49 ET Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-sem-dawn-vre-obtaining-fair-deals-for-their-shareholders-302727048.htmlSOURCE
More news about: Halper Sadeh LLP
Mar 13, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).Acurx's lead
More news about: Acurx Pharmaceuticals, Inc.
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product
More news about: Acurx Pharmaceuticals, Inc.
Mar 04, 2026, 16:15 ET Veris Residential Declares First Quarter 2026 Cash Dividend
JERSEY CITY, N.J., March 4, 2026 /PRNewswire/ -- Veris Residential, Inc. (NYSE: VRE) ("Veris Residential" or the "Company"), a forward-thinking, Northeast-focused, Class A multifamily REIT, today announced that the Company's Board of
More news about: Veris Residential, Inc.
Mar 04, 2026, 14:10 ET SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--ACLX, VRE, EHAB, and CECO
VRE) related to its sale to an investor consortium led by Affinius Capital in partnership with Vista Hill Partners. Under the terms of the proposed
More news about: Monteverde & Associates PC